01:04 , Jun 11, 2019 |  BC Extra  |  Company News

Why Brii Bio partnered with microbiome start-up Artizan

In its latest move to bring innovation to infectious diseases in China, Brii Bio has partnered with microbiome start-up Artizan, which is approaching IBD as if it were an infectious disease. Artizan Biosciences Inc. (New...
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
18:19 , Dec 7, 2018 |  BC Week In Review  |  Company News

Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Dec. 6, even as CEO Zhi Hong said the company is looking...
13:00 , Dec 6, 2018 |  BC Extra  |  Company News

Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Thursday, even as CEO Zhi Hong said the company is looking to...
22:57 , Nov 30, 2018 |  BioCentury  |  Finance

Global Dimensions

6 Dimensions Capital has invested in at least nine U.S. biotechs this year out of its inaugural U.S. dollar fund, and the pace is expected to continue. Those investments have caught the eye of the...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
16:54 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
11:00 , Jul 17, 2018 |  BC Extra  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...